DOI 10.1016/j.ejphar.2025.177353
Astragaloside IV prevents liver fibrosis by blocking glycolysis-mediated macrophage M1 polarization.
Аннотация
Hepatic fibrosis is a late-stage process of many chronic liver diseases. Blocking the fibrosis process will be beneficial to the treatment and recovery of the disease. Hepatic macrophages are a remarkably heterogeneous population of immune cells that play multiple functions in homeostasis and are central to liver fibrosis. Glycolysis-mediated macrophage metabolic reprogramming leads to an increase in the proportion of M1 macrophages and the release of pro-inflammatory cytokines. The present study aimed to investigate the therapeutic effect and mechanism of Astragaloside IV (AS-IV) against carbon tetrachloride (CCl4)-induced liver fibrosis. The study found that AS-IV is an effective agent for reducing the production of inflammatory factors in CCl4-induced liver fibrosis. It was also found that AS-IV blocks macrophage M1 polarization and relieves liver fibrosis. Mechanistically, AS-IV reduces the methylation level of the FoxO1 promoter region and then upregulates its expression. FoxO1 can inhibit the expression of key enzymes in the glycolysis pathway and block glycolysis-mediated macrophage M1 polarization. Our findings indicate that AS-IV is an attractive option for treating liver fibrosis.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.